

Index

A

- ABCB1, 22, 63, 64, 98–102
ABCC2. *See* Multidrug
resistance-associated protein 2
Abomasum, 35, 36, 115
AC-3933, 54
Acceptable daily intake, 14, 269–275,
279, 307
Acetaminophen, 40, 60, 65
Acetylation, 38, 40, 59, 60
Administration, 3, 9, 14, 16, 21, 24–27,
30, 32–34, 36, 37, 41–44, 52, 54, 55,
57, 58, 66, 80, 81, 83, 84, 86–88,
90–96, 98–101, 116, 121, 125, 142,
148, 164–166, 174–177, 179–181, 196,
204, 221, 245, 246, 253, 274, 275, 280,
292, 319, 320, 322, 324–327, 329, 331,
332, 335, 336
AhR. *See* Arylhydrocarbon receptor
Aims, 7–16, 21, 23, 38, 83, 93, 97, 317,
327, 329, 332, 336
AKR/J mice, 62
Alaskan malamute dogs, 61
Albumin, 65, 220
Allelic variants, 60
Allergenicity, 270
Allo-grooming, 32
Allometric scaling, 10, 11, 139–154
Allometry, 23, 148–152
Alpha 2 agonists, 7, 29, 30, 180–183
Altrenogest, 323
Amikacin, 32, 56
Amino-acetonitrile derivatives (AADs),
122, 123
Ampicillin, 32, 37
Anaesthesia, 29, 55, 68, 70, 162, 175
Anaesthetic. *See* Anaesthesia
Analgesic agents, 172–183
Androsterone, 61
Animal Medicinal Drug Use Clarification
Act (AMDUCA), 140
Anthelmintic (agents), 6, 9, 10, 35, 36, 84,
103, 115–120, 122–124, 206, 309
Antimicrobial, 6, 9, 10, 12–15, 26, 33, 36,
42, 44, 94, 125, 126, 128–132, 140, 200,
201, 206, 207, 227–258, 270, 274, 300,
306
resistance, 9, 10, 12, 13, 140, 194, 200,
206, 207, 227–258
therapy, 6, 13, 128, 132, 228, 233, 235,
242, 245–247, 250, 252, 253,
255–257
tolerance, 228, 250–253
Antipyrine, 40, 56, 141
Arsenic, 326
Arylhydrocarbon receptor, 65–66
Association of Official Racing Chemists
(AORC), 323
Atropine, 28, 58
Authorities, 14, 15, 171, 198, 220, 222,
246, 266, 273, 278, 283, 317, 320, 329,
333, 334
Avian renal cortex, 148
Azithromycin, 141, 142, 253

B

Basal metabolic rate, 143–146, 149
 Beagle, 6, 8, 23, 29, 38–40, 51–57, 63, 65, 86, 87, 141, 146
 Behaviour, 11, 21–26, 29, 30, 32, 33, 38, 41, 42, 161–166, 168, 169, 171–174, 176, 194, 217, 218, 254, 274, 275, 278, 294–300, 320, 323
 Benchmark dose (BDM), 269
 Benzimidazoles, 35, 122
 Benzo[a]pyrene, 60
 Bilirubin, 60, 65
 Bioavailability, 7, 24, 30, 32, 33, 35, 37, 43, 54, 82, 86, 88, 93, 95, 98, 99, 142, 179, 274, 295, 331
 Biotransformation, 37, 39, 198, 203, 206, 293
 Bird, 14, 15, 20, 24, 28, 34, 41–43, 145, 148, 151, 173, 174, 176, 177, 181, 194, 306, 309, 317
 Blood volume, 144, 319
 Body weight, 10, 30, 42, 52, 57, 141, 143–145, 147, 148, 151, 153–154, 221, 319, 335
 Boldenone, 318, 320, 325
 Bound residues, 274, 294
 Bovine respiratory disease, 128–130
 Breed, 5–8, 13, 21–25, 28, 38–40, 53, 55–58, 61–63, 65, 67, 68, 86, 88, 92, 100–102, 104, 164, 166, 199, 205, 206, 214, 216, 217, 219, 274, 302, 306, 317, 330, 334, 335
 Buffalo, 21
 Bufuralol, 52

C

Caecotroph, 34
 Caecum, 36, 37
 Calcium, 40, 66, 67, 182
 Cavalier King Charles spaniel, 25
 C57BL/6 mice, 62, 66
 Ceftiofur, 37
 Celecoxib, 6, 23, 40, 51, 52, 56
 Cephalosporins, 37, 125, 145
 Cestodes, 119–121
 CF-1 mice, 64
 Chemical contamination of food, 266

Chicken, 8, 25, 31, 34, 38, 40, 41, 143, 164, 215
 Choke, 35
 Cimetidine, 323
 Clearance (Cl), 5–8, 11, 23, 30–32, 38, 41, 51, 52, 54–57, 65, 82, 116, 141, 143, 147–151, 179, 325, 330, 331, 335
 Clindamycin, 37, 256
 Codex Alimentarius Commission, 267, 273, 278, 283
 Collective treatment, 20, 24–26, 41
 Collie dogs, 8, 63, 100, 101
 Comparative metabolism studies, 37, 38, 275
 Conjugative enzymes, 59–62, 66
 Contagious mastitis, 124
 Coprophagia, 8, 33–34
 Cortisol, 28, 324, 326, 327
 COX-1, 4, 5, 7, 178, 179
 COX-2, 4–7, 23, 86, 178, 179
 COXib, 5, 6
 Crigler-Najjar syndrome, 60
 Crop, 15, 34, 42, 307
 Cyclic depsipeptides, 122
 Cyclo-oxygenase (COX), 4, 5, 178, 179
 CYP1A2, 39, 54
 CYP3A12, 39, 52
 CYP2B11, 8, 39, 52, 56
 CYP2C21, 52, 53
 CYP2C41, 53
 CYP2D, 38, 53
 CYP2D2, 53
 CYP2D3, 53
 CYP2D6, 51–53
 CYP2D15, 40, 51, 52

D

D01-4582, 65
 Darbepoietin, 321
 Dark Agouti rat, 53
 DBA/2 mice, 62, 66
 Debrisoquine, 53
 Degree-days, 44
 Detection time, 16, 320, 323, 329, 334–336
 Developing countries, 194, 266, 288
 Dexamethasone, 28, 39, 101, 335
 Diazepam, 11, 53

Dichlorvos, 44
Diclofenac, 15, 43, 53, 307
Dogs, 4–8, 10, 11, 13, 15, 22–25, 28–34, 38–40, 45, 51–57, 59, 61–69, 81, 82, 84, 86–88, 90, 94, 96–98, 100, 101, 116–121, 123, 141, 143, 144, 149, 164–171, 175–179, 181, 182, 192–194, 205, 215–217, 221, 222, 254, 255, 266, 307, 317
Domestic animal species, 12, 21, 29, 33, 36, 37, 40, 50, 63, 79–104, 140–141, 165, 174–176, 195, 199–200, 204, 205, 216, 286
Domestic species, 13, 21, 22, 28, 29, 32, 33, 35, 39, 140, 142–143, 165, 174–176, 216, 222
Donkey, 5, 31, 32, 172
Doping, 15, 16, 34, 41, 315–336
Doramectin, 32, 101, 301
Dosage regimen, 8, 21, 23, 30–32, 102, 146, 149, 151, 152, 168, 201, 228, 236, 242, 246, 247, 250, 280, 331, 335, 336
Dose selection, 146, 228, 243, 257
Doxycycline, 26, 27, 37, 94
Drug delivery, 9, 12, 36, 37, 63, 79–104, 132, 195, 196, 200–202, 204–206, 286
Drug metabolism, 37–40, 44, 53–55, 60, 141, 149, 152
D-tubocurarine, 28
Duck, 41–43, 257

E

Echinococcus, 119, 120
Ecotoxicity, 304, 305, 308
Effect of feeding, 141, 142
Electroporation, 221, 222
Embryonic stem (ES) cells, 215, 216
Empathy, 29
Enrofloxacin, 43, 151
Enterocolitis, 36, 37
Environmental fate, 300, 308
Environmental mastitis, 124
Environmental risk, 14, 302–304, 308
Eprinomectin, 32, 116, 286
Erythropoietin (EPO), 16, 220, 316, 318, 320–322, 324, 325, 333
Estimated dietary intake, 271–273, 275

Estranediol, 320, 326
European Horserace Scientific Liaison Committee (EHSLC), 316, 318, 330, 334, 335
Exercise-induced pulmonary haemorrhage (EIPH), 319, 333
Export slaughter intervals, 283–284
Exposure assessment, 14, 268, 271–273, 277, 279, 288, 330, 332
Extensive metabolisers, 6, 8, 40, 51–54, 57, 58
Extrapolate, 23, 140, 145, 279
Extrapolations, 11, 24, 32, 39, 41, 90, 99, 140, 142–146, 148, 151, 152, 160, 198, 269, 309, 335

F

Fast acetylator, 59
Fast metabolisers, 62
First-pass metabolism, 54
Fish, 8, 9, 20, 25, 29, 34, 43–45, 140, 173, 174, 271, 292, 295, 300, 302, 303, 307, 309
Florfenicol, 96, 128–131, 231, 247, 249, 299, 307
Flunixin, 34, 37, 41, 147, 148, 150, 152, 179–181, 319, 332
Fluoroquinolones, 87, 102, 125, 126, 128, 229, 232, 235, 240, 249, 251, 257, 295, 301
Food-borne hazards, 266, 267, 279
Food consumption factors, 271–273
Food processors, 286–287
Food quality, 218
Force feeding, 42
Fore-gut fermentors, 140, 141
Formulation, 9, 24–26, 32–33, 35, 42, 80–98, 101, 103, 116, 121, 140, 142, 177, 204–207, 228, 250, 257, 274, 286, 287, 293, 294, 335, 336
Furosemide, 150, 319, 320
Future pharmacology, 8, 12, 13, 16, 20, 70, 193, 195, 196, 204

G

Gene targeting, 215, 220
Gene therapy, 13, 61, 216, 220–222

Genetic manipulation, 12, 214
 Genomes, 6, 12, 13, 50, 51, 214, 216–217, 222, 288
 Genotoxic carcinogens, 270, 271
 Genotyping, 23, 49, 53, 54, 63, 64, 67, 100, 101, 120, 216, 235, 250
 Giant Schnauzer dogs, 61
 Gills, 44, 87
 Gizzard, 42
 Glomerular filtration, 43, 148
 Glomerular filtration rate, 144
 Glucuronidation, 38, 40, 56, 60, 61
 Goat, 5, 13, 21, 28, 33, 38, 92, 117, 122, 140, 141, 150, 172–173, 214, 215, 219
 Good practice in the use of veterinary drugs (GPVD), 276, 278, 287
 Greyhound dogs, 8, 55–57, 68, 317
 Groundwaters, 297–298, 300, 301, 307, 308
 Growth hormone (GH), 16, 86, 205, 218, 221, 316, 318, 320, 324, 325333
 Gunn rat, 60, 61

H

Hair, 16, 90, 325
 Halothane, 6, 67, 68
 Hamster, 59–60
 Han/Wistar rats, 53, 60, 61, 64–66
 Harmonised screening limit (HSL), 316, 329, 333, 334, 336
 Hazard, 14, 15, 32, 86, 200, 239, 266–271, 273, 279, 285, 287, 307–309, 330, 332, 333
 Hazard characterisation, 14, 269–271, 273, 330, 332, 333
 Hazard identification, 14, 269, 273, 330
 Heart rate, 144, 181
 Heartworm, 88, 96, 101, 117, 121, 123
 Helminths, 114–124
 Hepatic clearance, 31
 Herbivores, 20, 38, 41, 149
 Herding breed dogs, 63, 101
 Hind-gut fermentors, 140, 141
 History, 3, 5, 12, 85, 103, 126, 143–149, 176, 178, 192, 207, 220, 267, 286, 287
 Hookworm, 119
 Humans, 3–16, 32, 37–39, 45, 50–54, 58, 59, 61, 62, 65–70, 80–87, 90, 91, 94, 95,

98–100, 102, 103, 119–121, 140, 141, 143, 144, 146, 148, 149, 160–169, 171, 174–177, 180, 182, 183, 193, 194, 196, 199, 200, 203–205, 207, 208, 214, 216–222, 228, 236–240, 245, 246, 249, 251, 255, 266–271, 274, 275, 279, 287, 292, 293, 301, 302, 305–309, 321

I

Import MRLs, 266, 283
 Induced pluripotent stem (IPS) cells, 12, 216, 222
 Inflammatory pain, 161
 Injection site residues, 278–280, 286
 International Equestrian Federation (FEI), 316–323, 329, 330, 333, 334
 International Federation of Horseracing Authorities (IFHA), 317, 319, 321, 330
 International trade in food, 266, 267, 278, 285, 288
 Interspecies differences, 20, 24–32, 34–37, 40, 151, 255
 Intra-mammary drug delivery, 92–93
 Irinotecan, 60
 Irrelevant plasma concentration (IPC), 16, 316, 329–334
 Irrelevant urine concentration (IUC), 16, 316, 329–334
 Isoniazid, 59
 Ivermectin, 8, 9, 23, 32, 33, 63, 64, 84, 86, 88, 91, 96, 98, 100–103, 116, 117, 119, 121, 299–301, 304, 306

K

Ketamine, 152, 183, 273
 Ketoconazole, 56, 101
 Ketoprofen, 152, 179–181, 273, 319
 Kidney, 9, 24, 40–41, 44, 56, 63, 64, 98, 199, 219, 221, 266, 271, 272, 275, 321
 Kleiber, M., 143, 145, 155
 Knockout, 63, 64, 215, 217, 218

L

Laboratory animals, 14, 20, 23, 51, 98, 140, 160, 166–169, 176, 183, 199, 269, 270
 LA Wistar rats, 61

Levamisole, 117, 122, 123, 152, 323
Licking, 9, 32, 33, 165
Lincomycin, 37, 234, 301, 304
Linear, 10, 141, 143–145, 148, 275,
281, 283
Linear extrapolation, 144, 145, 148
Liver fluke, 6, 115, 117, 118, 122
Local anaesthetics, 174–176, 323, 329, 332
Long-acting veterinary formulations, 26,
96, 103
Long-Evans rats, 66
Long-haired Whippet dogs, 63, 64
Loperamide, 23, 63, 101

M

Macrocyclic lactones, 84, 116, 117, 119,
123, 303
Macrolides, 10, 37, 42, 96, 125, 128, 231,
234, 255, 294, 295, 298, 301, 305
Malignant hyperthermia, 66–69
Mammals, 8, 11, 20, 28, 34, 41–44, 120,
142, 143, 145, 148, 151, 168, 173–175,
181, 214–217, 219
Marker residue, 271, 272, 274, 275,
277, 278
Market access, 285
Mastitis, 92, 93, 114, 124–127, 219,
251, 282
Maximum residue limits (MRLs), 14, 88,
208, 266–268, 271–279, 281–285, 287,
288, 307
MDR1. *See* ABCB1
Mdr1a, 63, 64
Mean absorption time (MAT), 141
Meclofenamic acid, 34, 37, 325, 332
Medication control, 316–318, 322–325,
327–330, 333, 334, 336
Medicine box, 323
Melatonin, 28
Metabolic scaling, 144–146, 148, 149, 155
Metabolism studies, 37, 56, 268, 274, 275,
277, 316, 324
Metaphylaxis, 26
Methadone, 56, 176
Methods of analysis for veterinary drug
residues, 267, 277, 278
Method validation, 146, 278
Methohexital, 55

Microfluidics, 12, 195, 200–203, 207, 208
Microinjection, 214, 215, 220
Mixed-breed dogs, 8, 53, 55–57, 63, 68
Monepantel, 117
Mongrel, 5, 141
Monogastrics, 35–38, 81, 83, 84, 140, 141
Monte Carlo simulations, 242, 335, 336
Morphine, 23, 30, 56, 84, 86, 90, 152,
176–178, 326
Moxidectin, 32, 33, 96, 101, 117, 119, 121
Multidrug resistance-associated protein
2 (MRP2), 64–65, 102
Mydriatic, 28

N

N-acetyltransferase, 59–60
Nandrolone, 318, 320, 321, 324, 326
Nano, 202, 204, 207
Naproxen, 6, 34, 306, 332
NAT. *See* N-acetyltransferase
NAT1, 40, 59, 60
NAT2, 40, 59, 60
Nematode, 9, 115–119, 121–123
Neophilia, 25
Neophobia, 25
Neuropathic pain, 161, 163, 166, 167, 171,
182–183
New Zealand white rabbits, 58
Nociception, 29, 160
Non-genotoxic carcinogens, 270, 271
Non-regulatory mechanisms for the control
of drug residues, 286–287
Non-steroidal anti-inflammatory drugs
(NSAIDs), 4–6, 15, 25, 37, 41, 43, 84, 86,
132, 160, 169, 178–183, 319, 323, 326
Non-viral vectors, 220, 221
No observed adverse effect level (NOAEL),
269
No observed effect level (NOEL), 14,
269–271, 288
Nuclear cloning, 215

O

Omasum, 35
Omeprazole, 333
Opioids, 160, 169, 176–178, 180–183
Oral absorption, 88, 103, 140–142

Organophosphate, 44, 58, 303
 Origins, 3, 8
 Ortholog (enzyme), 39
 Ostrich, 41, 146, 147, 173
 Oxidative enzymes, 38, 51–58, 66
 Oxybarbiturate, 55

P

Pain, 29, 159–183, 323
 Pain evaluation, 161
 Pain perception, 161, 165–167, 183
 Pain recognition, 167–174, 182
 Pale-soft-exudative pork, 66–68
 Paraherquimides, 122
 Paraoxonase, 58
 PARASOL, 123
 P450 cytochrome, 8, 31, 37–39, 51–57, 60, 99, 102, 142, 149
 Penicillin, 37, 57, 58, 125, 152, 233, 234, 251, 270
 Pentobarbital, 55, 56
 P-glycoprotein, 8, 22, 23, 50, 62–64, 98, 206
 P-glycoprotein efflux, 80, 98
 P-gp. *See* P-glycoprotein
 Pharmaceuticals, 4, 35, 80, 95, 104, 143, 146, 148, 149, 152, 193, 197, 204, 279, 286, 293, 295, 302, 305
 Pharmacodynamics, 5, 7, 8, 10, 19–45, 50, 144, 146, 174, 179, 200
 Pharmacogenetics. *See* Pharmacogenomics
 Pharmacogenomics, 8, 20, 21, 39, 49–70, 80, 104, 195, 199, 205–206
 Pharmacokinetic(s), 5–8, 10, 12, 13, 16, 19–45, 51, 52, 54–56, 65, 81, 82, 99, 119, 128–132, 140, 142–149, 151, 152, 164, 173, 174, 179, 196, 198–203, 241–250, 274, 288, 309
 Pharming, 13, 219–220
 Phenobarbital, 6, 55, 56, 100
 Phenylbutazone, 5, 37, 41, 152, 180, 319, 335
 Physiologically based pharmacokinetics (PBPK), 12, 24
 Pig, 5, 7, 8, 10, 23, 25–28, 31, 33, 38–40, 51, 67, 100, 132, 153, 177, 178, 180, 214, 216, 219, 288, 289, 305, 306
 Pigeon, 16, 41, 147, 153, 317, 325

PK/PD, 30, 144, 228, 241, 242, 244, 247–249, 316, 324, 329, 330, 332
 Plasma clearance, 23, 30, 31, 55, 56, 65, 151, 330, 331, 335
 Polymorphisms, 8, 13, 21, 39, 40, 50–70, 216
 Poor metabolisers (PM), 51, 54
 Population PK, 26
 Porcine stress syndrome (PSS), 66, 67
 Poultry, 8, 23–26, 37, 38, 41–45, 87, 117, 173, 266, 271, 294
 Pour-on, 32–33, 83, 88, 91, 101, 116, 294
 Praziquantel, 43, 86, 118, 120, 122
 Procaine, 57, 58, 323, 332
 Procedure for establishing MRLs, 275
 Producers, 14, 114, 124, 125, 280, 286–287
 Prophylaxis, 10, 26, 122, 319
 Propofol, 39, 56, 87
 Prostaglandin, 4, 28, 178
 Prostate, 28
 Pseudocholinesterase, 56
 Public health, 14, 81, 114, 119, 121, 132, 266, 278
 Pulmonary delivery of veterinary drugs, 81, 86–88

Q

Quarter horse, 68, 69

R

Ranitidine, 323
 Rationale, 7–16, 82, 87, 146, 317–318, 324–325
 Regulatory authorities, 14, 15, 198, 220, 222, 266, 278
 Renal portal system, 24, 44
 Reptiles, 20, 24, 44, 141, 145, 148, 151, 152, 155, 157, 173–177, 181
 Residue monitoring programmes, 266, 285
 Residues, 14, 15, 24, 26, 32, 33, 37, 43, 44, 88, 93, 95, 102, 116, 172, 194, 196, 200, 205, 265–288, 292–294, 298, 300–302, 307
 Resilience, 29
 Resistance, 9, 10, 12, 13, 26, 33, 69–70, 85, 98–100, 102, 103, 115, 122–124,

196, 200, 201, 207, 214, 218, 219,
227–258, 306

Reticular groove, 36

Reticulo-omasal orifice (ROO), 35, 36

Reticulo-rumen (RR), 35, 36, 116

Rhesus macaque, 59, 60

Risk analysis, 14, 267–285, 287, 316,
329–335

Risk analysis framework for food safety,
267–285

Risk assessment, 14, 198, 267–280, 284,
302, 307, 309, 316, 330–333

Risk communication, 267, 285, 334–335

Risk management, 14, 267, 280–284, 308,
316, 330, 333–334

Rumen, 35, 36, 83

Ruminants, 23, 29, 35, 36, 38, 84, 92–93,
114–116, 120, 122, 123, 140, 141, 164,
172, 173, 176, 179, 181, 194

Ryanodine, 67, 68

RyR1, 67–69

S

Safety factors, 14, 269–271, 288, 331

Salicylic acid (SA), 4, 35, 38, 41, 326, 327

Sarofloxacin, 43

Shepherd dogs, 63, 100, 221

Silken windhound dogs, 63

Single-nucleotide polymorphisms (SNPs),
13, 51, 61, 216, 217

Slow acetylators, 59

Slow metabolisers, 60, 62, 179

Small intestinal, 116, 141

Snakes, 141, 142, 174

SNPs. *See* Single-nucleotide
polymorphisms

Soil, 15, 115, 116, 292, 294–303, 306–308

Somatic cell counts (SCC), 125, 126

Species, 4–15, 19–45, 50, 51, 56, 58–60,
66, 68–70, 79–104, 115, 116, 119, 126,
140–149, 151, 152, 160–169, 171–177,
179, 181–183, 192–195, 198–200,
203–207, 215–217, 220, 222, 228, 230,
233, 237, 239–241, 244, 247, 248, 250,
251, 254, 255, 269, 270, 273, 275, 286,
296, 299, 300, 307, 309, 317

Specific minimum energy cost (SMEC), 145

Sprague-Dawley rats, 53, 65

SPS Agreement, 267

Stanozolol, 320

Succinylcholine, 30, 56, 66, 68

Sulphation, 56

Surface waters, 15, 293, 294, 299–301, 304,
307, 308

Swine respiratory disease (SRD), 127–132

T

Target tissue, 206, 275

Testosterone, 28, 39, 97, 267, 318, 320, 324,
326, 327

Theobromine, 326, 327

Theoretical maximum daily intake (TMDI),
271–273

Therapeutic proteins, 205, 219

Therapeutics, 3–9, 11–13, 34, 51, 70, 80,
191–208

Thiobarbiturates, 8, 55–57

Thiopental, 55–56

Thiopurine, 61–62

Thiopurine methyltransferase, 61–62

Thoroughbred horses, 57, 58, 68, 319

Threshold, 29, 31, 132, 169, 269, 271, 274,
320, 321, 326–327, 329, 332–334

Threshold dose, 269, 274

Tilmicosin, 128

Time-to-safe-concentration (TTSC)
method, 282–283

T_{max} , 141

TMPT. *See* Thiopurine methyltransferase

Topical veterinary delivery methods, 9,
90, 91

Toxicity, 7, 14, 58–61, 63, 64, 69, 82, 140,
169, 206, 269, 270, 275, 279, 297, 302,
305, 309

Tramadol, 182, 183

Transdermal veterinary drug delivery, 9,
80–82, 204

Transgenic, 12, 13, 69, 196, 214, 215,
217–220, 222

Transporters, 8, 9, 22, 62–65, 82, 97–104,
195, 199, 206, 218

Trichlorfon, 44

Trimethoprim/sulphonamides, 37, 128,
256, 298

- TR⁻ rats, 64, 65
 Tulathromycin, 128, 247, 249
 Turkey, 41
- U**
 UDP-Glucuronosyltransferase, 60
 UGT1A, 60–61, 66
 UGT2B2, 61
 Uncertainty factor, 331
 Unconjugated hyperbilirubinaemia, 60
 Uridine-diphosphate-glucuronosyl transferase (UDPT), 40
 Urinary pH, 40–41
 Urine, 16, 31, 33, 34, 40, 41, 182, 249, 293–295, 320, 323–327, 329, 331, 332, 334, 335
- V**
 Veterinarians, 32, 63, 81, 90, 95, 96, 145, 146, 149, 151, 161, 168, 194, 200, 286–287, 334, 335
 Veterinary drug delivery, 80–82, 87, 91, 95–97, 103, 195, 196, 200–202, 204–206, 286
 Veterinary drug interactions, 100–103
 Veterinary medicine, 4–6, 9, 13–15, 20–26, 32, 33, 37, 38, 41, 43, 44, 70, 81–83, 87, 90, 95, 97–100, 102, 103, 140, 142, 151, 152, 175, 182, 183, 194–196, 200, 204–208, 235, 242, 250, 251, 254, 268, 281, 291–309, 315–336
 Veterinary pharmaceutical industry, 193, 204, 279, 284, 286
 Veterinary vaccine delivery, 87, 88
 Villi, 141
- Vincristine, 63
 Viral vectors, 220, 221
 Visual analogue scores (VAS), 11, 161, 163, 168, 169, 173
 VKORC1, 70
 Volume of distribution (V_d), 5, 56, 116, 143, 145, 147, 335
 Vulture, 15, 43, 307
- W**
 Warfarin, 69–70
 Warfarin resistance, 69–70
 Warmblood riding horses, 58
 Wistar rats, 53, 60, 61, 64–66
 Withdrawal period, 14, 44, 274, 278–284, 286
 Withdrawal time, 14, 16, 44, 93, 198, 199, 207, 274, 280, 334–336
 World Anti-Doping Agency (WADA), 323
 World Trade Organisation (WTO), 267
- X**
 Xenografting, 13, 219
 Xylazine, 11, 29, 30, 180
- Y**
 Yarding, 36
 YM-64227, 54
- Z**
 Zero tolerance rule, 16, 283, 327–331
 Zoologic medicine, 145–148